secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001549595-25-000105
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Nurix director Lori Kunkel resigns; Roy Baynes named committee chair
--------------------------------------------------------------------

- Director Lori A. Kunkel, M.D. resigns from Board and committees effective September 1, 2025.
- Resignation not due to any disagreement with company on operations, policies, or practices.
- Board appoints Roy D. Baynes, MB.Bch., M.Med., Ph.D., as chair of Clinical and Commercialization Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000105/0001549595-25-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000105/nrix-20250819.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer